GenSight Biologics S.A. (LON:0RIM)
London
· Delayed Price · Currency is GBP · Price in EUR 0.2260
-0.0085 (-3.62%)
At close: Apr 17, 2025
GenSight Biologics Revenue
In the year 2024, GenSight Biologics had annual revenue of 2.63M EUR, down -11.44%. GenSight Biologics had revenue of 897.00K in the half year ending December 31, 2024, with 46.09% growth.
Revenue
2.63M EUR
Revenue Growth
-11.44%
P/S Ratio
13.55
Revenue / Employee
164.06K EUR
Employees
16
Market Cap
29.43M GBP
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.63M | -339.00K | -11.44% |
| Dec 31, 2023 | 2.96M | -1.90M | -39.08% |
| Dec 31, 2022 | 4.87M | -2.84M | -36.89% |
| Dec 31, 2021 | 7.71M | 269.00K | 3.62% |
| Dec 31, 2020 | 7.44M | 2.53M | 51.53% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.19B |
| HSBC Holdings | 48.93B |
| Shell | 227.10B |
| Unilever | 50.25B |
| Rio Tinto Group | 42.86B |
| RELX PLC | 9.43B |
| British American Tobacco p.l.c. | 25.87B |
| Rolls-Royce Holdings | 18.91B |